Karine Nozeret

Dr. Karine Nozeret

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
TBThomas Bazin
Thomas Bazin
KNKarine Nozeret
Karine Nozeret
CJCatherine Julié
Catherine Julié
DLDominique Lamarque
Dominique Lamarque
ETEliette Touati
Eliette Touati
Gastric cancer (GC) is a major cause of cancer-related mortality worldwide. It is often associated with a bad prognosis because of its asymptomatic phenotype until advanced stages, highlighting the need for its prevention and early detection. GC development is preceded by the emergence of gastric preneoplasia lesions (GPNLs), namely atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia (DYS). GC is currently diagnosed by endoscopy, which is invasive and costly and has limited effectiveness for the detection of GPNLs. Therefore, the discovery of non-invasive biomarkers in liquid biopsies, such as blood samples, in order to identify the presence of gastric preneoplasia and/or cancer lesions at asymptomatic stages is of paramount interest. This comprehensive review provides an overview of recently identified plasma/serum proteins and their diagnostic performance for the prediction of GPNLs and early cancer lesions. Autoantibodies appear to be promising biomarkers for AG, IM and early gastric cancer detection, along with inflammation and immunity-related proteins and antibodies against H. pylori virulence factors. There is a lack of specific protein biomarkers with which to detect DYS. Despite the need for further investigation and validation, some emerging candidates could pave the way for the development of reliable, non-invasive diagnostic tests for the detection and prevention of GC.

Verified
Journal Article
Open access
PDF file
QGQuentin Giai Gianetto
Quentin Giai Gianetto
VMValérie Michel
Valérie Michel
TDThibaut Douché
Thibaut Douché
KNKarine Nozeret
Karine Nozeret
Aziz ZaananAziz Zaanan
Aziz Zaanan
ETEliette Touati
Eliette Touati
Gastric cancer (GC) often presents a poor prognosis due to its asymptomatic phenotype at early stages. Upper endoscopy, which is the current gold standard to diagnose GC, is invasive with limited sensitivity for detecting gastric preneoplasia. Non-invasive biomarkers, such as blood circulating proteins, offer a promising alternative for the early detection of gastric lesions. In this prospective study, we identified plasma protein biomarkers for gastric preneoplasia and cancer using mass spectrometry-based proteomics in an exploratory cohort (n = 39). Fifteen promising protein candidates emerged to distinguish patient categories and were further confirmed by enzyme-linked immunosorbent assays (ELISA) in plasma samples from a validation cohort of 138 participants. Our predictive models demonstrated high classification performance with a minimal set of biomarkers. A four-protein panel (ARG1, CA2, F13A1, S100A12) achieved 94.1–98.2% AUROC (95% CI) for distinguishing cancer from non-cancer cases, while a five-protein panel (ARG1, CA2, HPT, MAN2A1, LBP) reached 97.3–99.5% AUROC (95% CI) for distinguishing cancer or preneoplasia from healthy or non-atrophic gastritis cases on the full cohort. Leveraging simple blood sampling, this strategy holds promise to detect high-risk gastric lesions, even at asymptomatic stages. Such an approach could significantly improve early detection and clinical management of GC, offering direct benefit for patients.

30 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TBThomas Bazin
Thomas Bazin
KNKarine Nozeret
Karine Nozeret
CJCatherine Julie
Catherine Julie
DLDominique Lamarque
Dominique Lamarque
ETEliette Touati
Eliette Touati
Gastric cancer (GC) is a major cause of cancer-related mortality worldwide, often associated with a bad prognosis because of its asymptomatic phenotype until advanced stages, highlighting the need for its prevention and early detection. GC development is preceded by gastric preneoplasia lesions (GPNL), namely atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia (DYS). GC is currently diagnosed by endoscopy, which is invasive and costly and has limited effectiveness for the detection of GPNL. Therefore, the discovery of non-invasive biomarkers in liquid biopsies, such as blood samples, to identify the presence of gastric preneoplasia and/or cancer lesions at an asymptomatic stage, is of paramount interest. This comprehensive review provides an overview of plasma/serum proteins recently identified and their diagnostic performance for the prediction of GPNL and early cancer lesions. Autoantibodies appear as promising biomarkers for AG, IM and early gastric cancer detection, along with inflammation and immunity-related proteins and antibodies against H. pylori virulence factors. There is a lack of specific protein biomarkers to detect DYS. Despite the need for further investigation and validation, some emerging candidates could pave the way to develop reliable, non-invasive diagnostic tests for the detection and prevention of GC.

30 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
QGQuentin Giai Gianetto
Quentin Giai Gianetto
VMValérie Michel
Valérie Michel
TDThibaut Douché
Thibaut Douché
KNKarine Nozeret
Karine Nozeret
Aziz ZaananAziz Zaanan
Aziz Zaanan
ETEliette Touati
Eliette Touati
Background Gastric cancer (GC) is often associated with a poor prognosis, due to its asymptomatic early stages. The current gold standard for diagnosing GC, upper endoscopy, is invasive and has limited sensitivity for detecting gastric preneoplasia such as dysplasia. Non-invasive biomarkers, such as circulating proteins in the blood, hold promise for the early detection of asymptomatic gastric lesions. Methods During an exploratory study, plasma samples from 39 participants, including patients diagnosed with different gastric pathologies (gastritis, preneoplasia, GC) and healthy controls, were analyzed using mass spectrometry-based proteomics. Data are available via ProteomeXchange with identifier PXD062315. Differentially abundant proteins were identified through pairwise comparisons and sparse Partial Least Squares Discriminant Analysis (sparse PLS-DA). Fifteen candidate proteins were selected and quantified by ELISA in plasma samples from the full cohort of 138 participants. Results Proteomic profiling identified 691 proteins in plasma samples. Pairwise comparisons highlighted up to 213 candidate biomarkers capable of distinguishing cancer patients from healthy controls, while distinguishing gastritis and preneoplasia proved challenging due to their similar proteomic profiles. Sparse PLS-DA identified 85 proteins that distinguish all patient groups. Subsequent ELISA validation confirmed Leptin as a promising biomarker for detecting gastric preneoplasia, particularly in women. Additionally, nine additional proteins (ATAD3B, IGFALS, JUP, LBP, MAN2A1, ARG1, CA2, HPT, KRT14) showed differential plasma levels across patients groups, with variations influenced by age and gender. Multi-biomarker prediction models incorporating factors such as age, gender, and H. pylori status, outperformed single-protein models. Using 4-fold cross-validation repeated 10 times, the top-performing models achieved high predictive accuracy, with mean AUROC values of 85.3% for classifications cancer vs. non-cancer and 83.9% for cancer/preneoplasia vs. healthy/gastritis. On the full cohort, optimal biomarker combinations reached AUROC values exceeding 94% for these classifications. Conclusions This study introduces a novel, non-invasive approach for predicting GC based on plasma protein concentrations across a broad spectrum of gastric pathologies. Predictive models, validated through robust cross-validation, demonstrated high accuracy using a limited panel of biomarkers. Leveraging simple blood sampling, this strategy holds promise for high-risk gastric mucosal lesions, including at asymptomatic stages. Such an approach could significantly improve early detection and clinical management of GC, offering direct benefit for patient outcomes.

1 January 2023 in Hépato-Gastro & Oncologie Digestive
Verified
Journal Article
Closed access
PDF file
TBThomas Bazin
Thomas Bazin
KNKarine Nozeret
Karine Nozeret
ETEliette Touati
Eliette Touati
DLDominique Lamarque
Dominique Lamarque